Human basal cell carcinoma: the induction of anagen hair follicle differentiation by Morgan, H. J. et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/126752/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Morgan, H. J., Benketah, A., Olivero, C., Rees, E., Ziaj, S., Mukhtar, A., Lanfredini, S. and Patel,
G. K. 2020. Human basal cell carcinoma: the induction of anagen hair follicle differentiation.
Clinical and Experimental Dermatology 45 (3) , pp. 309-317. 10.1111/ced.14108 file 
Publishers page: http://dx.doi.org/10.1111/ced.14108 <http://dx.doi.org/10.1111/ced.14108>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
 
 
Human basal cell carcinoma: the induction of anagen hair follicle 
Differentiation 
 
H. J. Morgan,1 A. Benketah,1 C. Olivero,1 E. Rees,1 S. Ziaj,1 A. Mukhtar,1 S. Lanfredini1 and 
G. K. Patel1 
1European Cancer Stem Cell Research Institute, School of Biosciences, CardiffUniversity, Cardiff, UK 
doi:10.1111/ced.14108 
 
Summary Background. Consistent with cancer stem cell driven pattern of growth, human 
basal cell carcinomas (BCCs) demonstrate differentiation along hair follicle (HF) 
lineages. 
Aim. To define the pattern of differentiation and therapeutic targets that promote 
BCC differentiation and therefore BCC cancer stem cell exhaustion. 
Methods. An alkaline phosphatase substrate kit was used to determine dermal 
papilla cells within the BCC stroma. Autonomous HF cycle-dependent gene expression 
was identified by analysis of the human homologues of a murine gene set (total 
2289 genes) that is differentially expressed in hair cycle phases. The findings were 
validated by quantitative real-time PCR and immunofluorescence, as well as in vitro 
transforming growth factor (TGF)-b2 stimulation of BCC cancer stem cell colonies. 
Results. As in the HF, keratin expression in the inner root sheath and matrix in 
BCC correlated with proliferative index and was tightly regulated, despite the 
absence of dermal papilla cells. Cross-species microarray analysis comparing human 
BCC and murine synchronous HF growth cycle datasets revealed 74% concordance 
with telogen differentiation compared with anagen (23%, P < 0.01) and catagen 
(49%; P < 0.01). Incomplete anagen differentiation within BCC was characterized by 
reduced expression of the anagen master regulator DLX3 (_5.5-fold), and increased 
expression of telogen-associated genes: AEBP1 (2.2-fold), DEFB8 (35.3-fold), MMP3 
(106.0-fold) and MMP12 (12.9-fold). Restoration of dermal papilla signals by 
in vitro addition of TGF-b2 enhanced anagen differentiation. 
Conclusion. Our findings show that BCC cells differentiate along HF lineages and 
may be susceptible to exogenous HF cycle modulators. 
 
Introduction 
During embryogenesis, the hair follicle (HF) miniorgan emerges from a well-choreographed and coordinated reciprocal 
pattern of growth factor signalling between the epidermis and dermal condensate. 1 Likewise, the postnatal HF is 
dynamic, and undergoes cyclical growth (anagen), apoptosis (catagen) and rest (telogen) phases during the hair cycle. 
As in hair development, the hair cycle is also regulated by coordinated release of soluble signalling molecules 
from the epithelium, in particular the HF bulge and bulb, the mesenchymal dermal papilla (DP) and the surrounding fat. 
Alkaline phosphatase (ALP) activity is routinely used as a DP marker, and it is evident throughout the hair cycle, with 
expression being maximal in early anagen and decreasing in the proximal portion after mid-anagen. Transition from 
telogen to anagen is initiated by the secretion of transforming growth factor (TGF)-b2 ligand by DP cells, and the signal 
is received through the TGF-b receptor II, expressed on bulge and bulb keratinocytes.2 Through direct regulation of 
Tmeff1, TGF-b2 inhibits signalling of bone morphogenic protein (BMP), a hallmark of quiescence during telogen. This 
is followed by reduced BMP4 production by the DP and bulb, followed by increased expression of Noggin and 
downregulation of Bmpr1a. Simultaneously, there is an increase in BMP4 expression in the dermis.3 Anagen HF growth 
and differentiation is associated with an increase in soluble Wingless-ints (Wnt3, Wnt4, nt10a/b and Wnt11), which 
are released by bulb matrix cells.4 Later, accumulation of TGF-b1 and fibroblast growth factor (Fgf) 18, produced by 
bulge keratinocytes, induces catagen. 5,6 Accumulation of BMP2 and BMP4 from epithelial and dermal compartments 
contributes to HF quiescence during telogen.7 The hair cycle also defines the HF differentiation patterns, as evidenced 
by microarray analysis of murine HFs in synchronous growth.8,9 The fully formed HF during anagen generates the hair 
shaft growth, comprised of an outer root sheath (ORS), companion layer, four inner root sheath (IRS) layers and four 
hair shaft layers. Each HF layer has a distinct and lineage-specific differentiation p tern, which is characterized by 
specific keratin expression patterns.10 
 
Human basal cell carcinomas (BCCs) are thought to be derived from HF bulge keratinocyte stem cells (KSCs) as 
evidenced by the following: (i) BCC growth is frequently observed on hair-bea ing skin; (ii) BCC cells resemble basal 
cells of the HF ORS; and (iii) the human HF bulge KSC cell surface marker CD200 is also expressed on human BCC 
cancer stem cells.11 Lineage tracing experiments in transgenic mouse models of BCC have shown that BCCs are 
derived from HF bulge KSCs and demonstrate HF differentiation.12,13 BCC growth is dependent upon and 
characterized by an essential dense and inductive fibroblast-rich stroma that artificially fractures during histological 
processing. The role of the BCC stroma, which may or may not contain DP cells, in human BCC differentiation is 
unknown. Further understanding of the pattern of BCC differentiation is important, as we know that promoting 
 
 
epidermal differentiation by administration of retinoids can hinder squamous cell carcinoma (SCC) growth. Therefore, 
in the current study, we sought to define the pattern of BCC differentiation, nd elucidate potential therapeutic targets 
that might promote BCC differentiation and result in BCC cancer stem cell exhaustion. 
 
Methods 
BCC, SCC and normal skin tissues were obtained after approval by the UK NHS R&D and Local Research Ethics 
Committee (09-WSE-02–1). Patients were recruited from Hywel Dda and Cardiff and Vale University Health Boards, 
and all gave informed written consent. 
 
Tissue dissociation and in single cell culture 
Tissue for cell culture was processed as previously described.14 BCC cells were plated onto a feeder layer (50 Gy-
irradiated 3T3 murine fibroblasts) and keratinocyte serum-free media (Gibco, Thermo Fisher Scientific, 
Loughborough, Leicester, UK) supplemented with 20 ng/mL epidermal growth factor(Pep otech IEC Ltd, London, 
UK), 10 ng/mL FGF-2 and 0.15 ng/mL bovine pituitary extract, 25 U/mL of penicillin, 25 μg/mL streptomycin and 10 
μg/mL amphotericin (all Gibco, Thermo Fisher Scientific) was used. 
Microarray 
For each biological replicate 500 ng of high-quality total RNA was labelled using an RNA kit (Illumina TotalPrep 
RNA Amplification Kit; Ambion, Thermo Fisher Scientific) and hybridized to a BeadChip array (HumanHT-12 v4; 
Illumina, Cambridge, UK) according to the manufacturer’s instructions. The resulting data were analysed using the 
Bioconductor packages in the R statistical program for data processing for all the subsequent steps. For analysing 
Illumina microarray data, the Lumi package was used for assessing quality control of the samples, and removing 
outliers, before transforming the data using variance stabilizing transformation, and normalizing the conditional 
quantile normalization method. Finally, genes were annotated and mapped at the probe level using the 
lumiHumanAll.db and luminHumanIDMapping programs respectively. 
Microarray data for the first two synchronized murine hair growth cycles were obtained from the data of Lin et al.8 via 
the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo). 
Log fold changes and z-scores were generated from both the Lin et al.8 dat set and our own microarray dataset.8 The 
panel of 80 homologous genes of interest were compared between the two microarray datasets using the online tool 
Morpheus (https://software.broadinstitute.org/morpheus) to generate heat maps and to perform Pearson correlation 
and hierarchical clustering.  
RT2 Profiler Array 
RT2 Profiler PCR Array (PAHS-035Y) was undertaken to determine the expression of 84 TGF-b/BMP signalling 
pathway regulated genes in six BCC, three SCC and five normal skin samples, in accordance with the manufacturer’s 
instructions (QIAGEN, Manchester, UK). Briefly, cDNA was synthesized using the RT2 First Strand Kit and mixed 
with the ready-to-use PCR mastermix (both QIAGEN) and subsequently added to the RT2 Profiler PCR Array plate 
(384-well) containing the SYBR_ Green-optimized primer assays of interest. The plate was run on the QuantStudio 7 
Flex Real-Time PCR System (Thermo Fisher Scientific).  
Immunofluorescence labelling 
Immunofluorescence on frozen sections was performed using standard techniques as previously described.14,15 For the 
list of antibodies used, see Table S1. Images were acquired using a camera (Axiocam; Zeiss, Cambourne, 
Cambridgeshire, UK) and processed using ImageJ software (https://imagej.nih.gov/ij/download.html). 
Alkaline phosphatase staining 
Sections were cut on a cryostat and fixed in acetone (Thermo Fisher Scientific) for 15 min, air-dried and washed for 
10 min in Tris buffer (pH 8.2). The ALP substrate kit (Vectastain; Vector Laboratories Ltd, Peterborough, UK) 
consisted of three reagents; two drops of reagent 1 were mixed with 5 mL of Trisbuffer, followed by addition of two 
drops each of reagents 2 and 3. The sections were then incubated in the above substrate mixture for 30 min, followed 
by washing in tris buffer. The slide was counterstained with haematoxylin (Sigma-Aldrich, Gillingham, Dorset, UK) 
for 5 min and mounted. 
Quantitative real-time PCR 
Real-time quantitative reverse transcription analysis was performed on the QuantStudio 7 Flex Real-Time PCR 
System (Thermo Fisher Scientific). Total humanspecific b-actin was used as the housekeeping g ne. Primer details are 
described in Table S2. 
In vitro transforming growth factor-b stimulation 
BCC colonies were established as previously described15 an  treated in triplicate as follows: fresh media and fresh 
media with 100 μmol/L TGF-b2 (Peprotech IEC Ltd). Each well was photographed under an inverted light 
microscope with a 29 objective lens and a digital camera system (Axiocam; Zeiss). Photographs were converted 
into binary images and both colony number and size were determined using Image J software (NIH, Bethesda, MD, 
USA). After 48 h, RNA was extracted from each well and reverse transcribed into cDNA. 
Statistical analysis 
Paired t-test and Fisher exact tests were used to compare real-time PCR data and microarray conco dance 
respectively, using GraphPad Prism software (Graph- Pad, La Jolla, CA, USA). 
 
 
 
 
 
Results 
Regulation of hair follicle keratin expression in basal cell carcinoma is not dependent on dermal papila Labelling of hair follicle 
tissue sections with versican and a-smooth muscle actin both also labelled the dermal sheath fibroblasts (Fig. 1a). The 
hair bulb and DP expressed CD56, BMPs and BMP receptor 1a, but these are also not specific for the DP (Fig. 1b,c). 
After optimizing ALP labelling in HFs (Fig. 1d), expression was determined in eight BCC samples (Fig. 1e). 
Although ALP accurately labelled the DP, additional positive cells arranged in linear patterns were observ d within 
the surrounding stroma, suggestive of dermal blood vessels, both in the BCC and the normal HF tissue. Using 
immunofluorescence, ALP did indeed simultaneously detect DP in the HF, which remained CD31-negative, 
but dual positive labelling was observed elsewhere in the stroma (Fig. 2, upper row). In BCC sections, all 
ALPpositive cells within the stroma coincided with CD31-positive endothelial cells (Fig. 2), although not all 
CD31-positive endothelial cells were ALP-positive.  
Incomplete anagen hair follicle differentiation in basal cell carcinoma 
Of the 89 murine hair cycle-dependent genes, derived from microarray data gene sets of the first two synchronized 
murine hair growth cycles (Tables S4–12), 80 human homologues were identified. We found that 38 were upregulated 
(19 significantly upregulated) and 42 downregulated (16 significantly downregulated) within our BCC compared with 
the human scalp HF dataset (Table S3). Concordant gene regulation was demonstrated in 59 (74%) of the 80 telogen 
genes, but only 23% of the anagen genes (P < 0.01) and 49% of the catagen genes (P < 0.01). Using the raw dataset, 
we determined and compared the log fold change and zscores for the entire dataset and the 80 human homologue 
gene set (Fig. 3a,b). The log fold change analysis clustered BCC with telogen (Pearson correlation coefficient 
0.30), while the z-score transformed data clustered BCC between telogen and anagen differentiation (Pearson 
correlation coefficient _0.24). BCC genes were concordantly regulated as observed in murine telogen using a second 
publicly available dataset (Tables S13 and S14). Analysis of the human homologues of the telogen murine datasets 
identified four genes that were significantly upregulated (DEFB4, AEBP1, MMP3 and MMP12; Fig. 3c,d) and nine 
that were significantly downregulated in BCC, which included the anagen master regulator DLX3 (Fig. 3c) and IRS 
keratins (KRT35, KRT73, KRT71, KRT25, KRT27; microarray data not shown). 
Induction of further anagen differentiation in basal cell carcinoma 
Wnt ligand levels and Wnt-regulated gene expression were lower in BCC than that in sc lp skin and SCC (Fig. 4a,b). 
BMP2 and -4 expression (Fig. 4c) was counterbalanced by increased expression of BMP antagonists Noggin (Fig. 4d), 
gremlin1 and follistatin as previously described in BCC. Equal numbers of BCC cells established over 2 weeks in 
primary cell co-cultures were treated with Noggin or TGF-b2 for 48 h, commensurate with doses used to promote 
anagen in murine HF studies. Addition of Noggin and TGF-b2 alone or in combination with in vitro BCC cell 
culture, despite a relatively short half-life, was sufficient to increase DLX3 expression after 48 h (Fig. 4e), reversed 
telogen-associated gene expression (DEFB4 and MMP3, but not MMP12) and also downregulated BCC-associated 
expression of KRT75. 
 
Discussion 
Even though BCC growth is driven by perturbation of a single oncogenic pathway, BCC differentiation is not 
restricted to a single differentiation lineage, but instead appears to recreate the complex patterns observed within the 
HF mini-organ during anagen. In the current study, it was found that BCC anagen HF differentiation is incomplete 
due to: (i) absence of DP cells; (ii) low DLX3 expression; (iii) BMP expression; and (iv) low Wnt liga ds and Wnt-
regulated gene expression. This incomplete anagen is characterized by: (i) the absence of hair shaft growth; (ii) lower 
expression of HF-specific keratins; and (iii) expression markers of telogen AEBP1 and beta-defensin 4. We have 
shown that the exogenous addition of TGF-b2 further promoted anagen growth pattern in vitro, highlighting a novel 
approach to promote BCC differentiation that may be of therapeutic importance. These findings also emphasize the 
importance in BCC of epithelial mesenchymal interactions that define the spatial organization, growth and function of 
tissues in embryogenesis, adulthood and cancer. 
 
Conclusion 
In summary, we found that BCCs do not contain HF DP cells. Using the murine HF growth cycle microarray 
datasets8,9 we showed that BCCs demonstrate incomplete anagen differentiation by BCC microarray an lysis, 
immunofluorescence, quantitative realtime PCR and in vitro-based experiments. Importantly, we showed that the 
exogenous addition of growth factors can promote BCC differentiation. These findings demonstrate a novel pattern of 
BCC differentiation that is amenable to therapeutic targeting. 
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What’s already known about this topic? 
• Promoting differentiation in combination with Smoothened antagonist therapies (e.g. vismodegib) can lead to 
eradication of BCCs. 
• Regulation of differentiation in BCC is similar to that observed in the HF ORS, matrix and IRS. 
 
What does this study add? 
• Human BCC growth and differentiation is not dependent on DP cells. 
• HF differentiation in human BCCs is hair cycledependent, in which anagen differentiation is bl cked and can be 
overcome by addition of TGFb, a known HF cycle regulator. 
• There is a specific pattern of human BCC differentiation along perturbed hair cycle-dependent HF lineages, which is 
amenable to exogenous therapeutic manipulation. 
• Using agents that promote HF differentiation may prove effective in BCC therapy, most notably when used in  
combination with Smoothened antagonists such as vismodegib. 
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Figure 1 To identify dermal papilla by immunolabelling or staining, human scalp containing hair follicles (HFs) was labelled with (a) 
versican, (b) CD56 and (c) bmpr1a antibodies. (d) Tissue samples were also immunohistochemically stained with alkaline phosphatase 
(ALP). (e) Samples of human scalp containing HFs and eight sample basal cell carcinoma (BCC) tissue sections were stained for ALP. 
All sections were counterstained with haematoxylin. All scale bars: 100 μm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Dermal papilla cell labelling of hair follicle (HF) and basal cell carcinoma (BCC) tissue sections with triple-label 
immunofluorescence 
of HF bulb and BCC tissue sections: K17 (blue), alkaline phosphatase (ALP; red) and CD31 (green). Immunolabelled tissue sections 
were visualized and photographed under a fluorescent microscope under 920 magnification, then processed using ImageJ 
software. All scale bars: 100 μm 
 
 
 
 
Figure 3 Basal cell carcinoma (BCC) demonstrates telogen hair follicle (HF) cycle differentiation: (a) bioinformatic microarray data 
comparison 
of BCC and murine HF growth cycle gene set, with all human homologues (n = 80) and (b) BCC genes showing significant differential 
expression. (c) Quantitative real-time PCR analysis of BCC samples for genes overexpressed (DEFB8, AEBP1, MMP3 and 
MMP12) and underexpressed (DLX3) in telogen. (d) Immunofl orescence analysis of beta-defensin 4 and Aebp1 (green) together with 
K14 (red) antibody-labelled BCC tissue. Immunolabelled tissue sections were visualized and photographed undera fluorescent microscope 
under 910 and 920 magnification, then processed using ImageJ software. All scale bars: 100 μm. 
 
 
 
 
 
Figure 4 Induction of telogen to anagen differentiation in basal cell carcinoma (BCC): (a) microarray data expression analysis of Wnt 
ligands in BCC, squamous cell carcinoma (SCC) and human sc lp containing hair follicles (HFs), and (b) Wnt-responsive genes. (c) 
Double- 
label immunofluorescence of BCC tissue sections, with BMP2 or -4 (green), K14 (red) and DAPI (blue). (d) RT2 profilerTM analysis of 
Noggin expression in BCC, SCC and HF. (e) Quantitative real-time PCR of human BCC cultures after treatment with Noggin, transforming 
growth factor (TGF)-b and combination compared with endogenous control and untreated culture. Immunolabelled tissue sections 
were visualized and photographed by fluorescent microscope with 910 and 920 magnification then processed uing ImageJ software. 
All scale bars: 100 μm. *P < 0.05 and **P < 0.01. 
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Supporting Information 
Additional Supporting Information may be found in 
the online version of this article: 
Table S1. List of antibodies used for immunofluorescence. 
Table S2. List of TaqMan primers used in quantitative 
real-time PCR. 
Table S3. Validated gene set. 
Table S4. Cluster 1–4: Peak early anagen. 
Table S5. Cluster 5–6: Peak mid anagen. 
Table S6. Cluster 7–8: Peak late anagen. 
Table S7. Cluster 9–12: Drop in catagen. 
Table S8. Cluster 13: Drop in catagen. 
Table S9. Cluster 14–15: Peak in catagen. 
Table S10. Cluster 16–18: Sharp rise in catagen. 
Table S11. Cluster 19–21: Slow rise in catagen. 
Table S12. Cluster 22– 4: Drop during catagen. 
Table S13. Genes overexpressed in telogen. 
Table S14. Genes underexpressed in telogen. 
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